BLACK DIAMOND THERAPEUTICS, INC. Debt Securities, Available-for-sale, Amortized Cost
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) had Debt Securities, Available-for-sale, Amortized Cost of $91.38 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $91.38M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $88.22M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $107.56M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $104.50M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $91.38M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $88.22M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $107.56M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $104.50M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $112.86M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $53.99M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $62.11M 10-K · filed 2026-03-16 |
| 2024-09-30 | $89.15M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $90.28M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $89.87M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $75.21M 10-K · filed 2025-03-06 |
| 2023-09-30 | $86.64M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $48.30M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $65.40M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $90.32M 10-K · filed 2024-03-12 |
| 2022-09-30 | $92.71M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $107.30M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $127.43M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $144.40M 10-K · filed 2023-03-09 |
| 2021-09-30 | $188.26M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $225.94M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $275.62M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $279.85M 10-K · filed 2022-03-17 |
| 2020-09-30 | $276.00M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $280.01M 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |